key: cord-0892127-f0v6e886
authors: Shoja, Zabihollah; Jalilvand, Somayeh; Latifi, Tayebeh; Roohvand, Farzin
title: Rotavirus VP6: involvement in immunogenicity, adjuvant activity, and use as a vector for heterologous peptides, drug delivery, and production of nano-biomaterials
date: 2022-03-15
journal: Arch Virol
DOI: 10.1007/s00705-022-05407-9
sha: 4340ae3e308838b25adf4a0eb0c2b09e50c76770
doc_id: 892127
cord_uid: f0v6e886

The first-generation, live attenuated rotavirus (RV) vaccines, such as RotaTeq and Rotarix, were successful in reducing the number of RV-induced acute gastroenteritis (AGE) and child deaths globally. However, the low efficacy of these first-generation oral vaccines, coupled with safety concerns, required development of improved RV vaccines. The highly conserved structural protein VP6 is highly immunogenic, and it can generate self-assembled nano-sized structures, including tubes and spheres (virus-like particles; VLPs). Amongst the RV proteins, only VP6 shows these features. Interestingly, VP6-assembled structures, in addition to being highly immunogenic, have several other useful characteristics that could allow them to be used as adjuvants, immunological carriers, and drug-delivery vehicles as well as acting a scaffold for production of valuable nano-biomaterials. This review provides an overview of the self-assembled nano-sized structures of VP6-tubes/VLPs and their various functions.

Rotavirus (RV) virions are triple-layered particles with icosahedral symmetry, enclosing 11 segments of doublestranded (ds) RNA, the viral RNA-dependent RNA polymerase (VP1), and the capping enzyme (VP3) [14, 39, 45] . RVs were first identified in animals [1, 75] , and later in humans [12, 13, 48, 63] . They are prominent causative agents of acute gastroenteritis (AGE) in children less than 5 years of age worldwide [93, 94, 112] and were responsible for around 500,000 deaths each year, prior to the beginning of global vaccination programs [112] . However, after the introduction of RV vaccines, the number of RV deaths decreased to 215,000 in 2013 [113] and then to 128,500 in 2016 [115] , globally. The vaccines that have been introduced include live attenuated oral vaccines, which are used at both the global (RotaTeq and Rotarix) [7, 8, 19, 20, 106, 119, 120] and national (RotaVac, Rotavin-M1, ROTASIIL, and Lanzhou lamb RV vaccines) [7] [8] [9] [10] 19 , 20, 59] levels. Despite the success of live attenuated oral vaccines in reducing the number of RV deaths worldwide, several concerns, such as efficacy, safety, and cost, have impeded their development, and novel alternative approaches to producing RV vaccines are being considered.

Among the RV proteins, the highly conserved structural protein VP6 was the first RV antigen (Ag) to be used for classification of RV strains. Accordingly, 10 groups (A-J) and two new tentative groups, K (for RVC-like group) and L (for RVH-like group) [6, 58, 62, 82, 87] , have been identified based on serological cross-reaction to the VP6 protein (group Ag). In addition, further VP6 classification into four subgroups (SGI, II, I + II, and non-I, non-II) based on reactivity with one, both, or neither of the monoclonal antibodies (mAbs) 255/60 and 631/9 has been proposed [52, 73] . However, other classification systems based on the genotypes of the outer capsid proteins VP7 and VP4, the glycoprotein 36G, and the protease-sensitive protein 51P have also been described [58, 69, 79, 81] . Furthermore, a whole-genomebased RV classification system has also been introduced that Handling Editor: Tim Skern.

Zabihollah Shoja and Somayeh Jalilvand have contributed equally as first author.

defines the genotypes of all 11 genomic RNA segments [79, 80] .

Besides being a highly immunogenic protein containing dominant antigenic epitopes, VP6 is also the most abundant viral protein and is capable of self-assembling into complex structures when expressed in isolation under defined conditions. These structures include trimeric, spherical, and tubular forms and sheet structures. Structural proteins from several viruses such as hepatitis B virus (HBV), human papilloma virus (HPV), human immunodeficiency virus (HIV), adeno-associated virus (AAV), hepatitis C virus (HCV), norovirus (NoV), human influenza virus, respiratory syncytial virus (RSV), coronaviruses, and bacteriophages have also been shown to be capable of producing immunogenic VLPs that can be used for vaccine development [88, 100] . However, VP6 is one of only a limited number of structured viral protein assemblies that are able to be used as carrier proteins with strong adjuvant activity. Moreover, VP6 is one of the very few immune-carrier/adjuvant systems that are capable of producing tubular forms and sheet structures. One well-known example of a viral carrier protein is the highly immunogenic hepatitis B core antigen (HBcAg), which is used as a carrier for heterologous Ags/epitopes to enhance antibody production and T-cell responses directed to heterologous antigens [105] . However, despite the powerful adjuvant activity of HBcAg VLPs, they do not make tubular forms or sheet structures like VP6.

The first biochemical analyses of the native oligomeric structure of VP6 were performed using infected cells or virus particles, selectively removing VP6 from double-layered particles (DLPs; VP2/6) [11, 51] . In parallel, several other researchers attempting heterologous expression of RV VP6 also reported the production of this protein in its native oligomeric state [2, 17, 37, 38, 67, 72, 89, 90, 126, 127] and suggested the use of nano-tubular (tube)/nano-spherical (VLP) structures of VP6 as an immunological carrier for heterologous and homologous Ags [49, 102, 111] as well as a drug delivery system [126] . Of note, these structures were shown to react with VP6-specific mAbs, indicating that their native immunoreactive determinants were conserved [44] . It has also been shown that self-assembly of VP6 into nanoscale structures can create multifunctional scaffolds for construction of organized nanoparticle-based biomaterials with novel functions and characteristics [99] . Therefore, based on its strong immunogenicity, conserved characteristics, and ability to self-assemble, VP6 is being considered as both an antigen and a platform to develop alternative non-living RV vaccine candidates, as well as an organized nanoparticlebased structure for biomedical applications.

We have previously reviewed several promising VP6based vaccine platforms (VP6 DNA vaccine, VP6 recombinant protein vaccine, and VP6-VLPs vaccine) [3, 60] that were able to induce heterologous cross-protective immunity to RV in animal models. In the present article, we provide an updated overview of potential applications of VP6 tubes/VLPs as an adjuvant, immunological carrier, and drug delivery tool and their use in the design of a new generation of vaccines and as a scaffold for generation of nano-biomaterials.

Various expression systems (Fig. 1A) , from the prokaryotic E. coli [2, 72, 126] [90] , and plant cells [37, 89, 127] have been used to produce multimeric VP6 structures that morphologically resemble VP2-and VP6containing VLPs, as well as tubes.

The assembly of VP6 into different structural forms depends on the pH, ionic strength, and concentrations of the divalent cations Ca +2 and Mg +2 [68, 101] . Spherical multimeric structures are formed in the pH range of 3.5-5.5, whereas large and small tubular multimeric structures are formed in the pH range of 5.5-7 and above 7, respectively [68, 86] . In contrast, structured protein assemblies of VP6 are disassembled at Ca +2 concentrations above 10 mM [68, 86] and at increased oxidant concentrations during the stages of the particle formation [25] . The formation of VP6 nanotubes in vitro was first reported in 1987 [101] , but recently, a simple and efficient ultrafiltration method to purify VP6 tubes/VLPs in vitro was developed [67] . More recently, an easy and reproducible method to produce VP6 nanotubes from VP6 monomers was introduced that not only offers a novel approach to producing VP6 tubes in vitro but also makes it possible to modulate the length of the tubes [104] . Progress in the production/purification and development of various VP6 tubes/VLPs has provided the opportunity to investigate their potential application as immunogens, adjuvants, delivery tools, and nano-biomaterials (Table 1 ).

Various RV VP6 Ag-encoding vaccine modalities, including DNA vaccines [3, 26-28, 36, 56, 57, 60, 74, 121, 123, 125, 128] , subunit vaccines (harboring recombinant VP6 protein) [2, 3, 29-35, 40, 46, 60, 66, 83-85, 107, 116, 117, 121, 124, 127] , and self-assembled structures [3, 15, 16, 18, 44, 60, 64, 76-78, 95, 108, 110, 121] have been reported to induce an immune response and/or protection in animal models. The results of these animal immunization studies have indicated that, even in the absence of neutralizing Abs, immune responses to VP6 alone might be protective. It is known that neutralizing epitopes are only present on the VP4 and VP7 proteins of RV. Therefore, the observed protection of animals immunized with VP6 preparations lacking VP4 and VP7 proteins indicates that neutralizing Abs (directed against VP4 and VP7) might not be needed for protection against RV infection [3, 60] . Similarly, there have been several reports showing that non-neutralizing Abs are capable of clearing RV infection, suggesting the occurrence of intracellular inhibition of RV infection by IgA [4, 21, 47] and IgG [22] following transcytosis. Interestingly, among the various VP6 preparations, self-assembled VP6 structures such as VP6 tubes/VLPs have been reported to be the strongest immunogens, not only inducing a stronger immune response and a higher level of immunogenicity and protection [95] but also exhibiting adjuvant and immunological carrier properties [15] . The RV protein VP6 is capable of self-assembling into nanosized spherical and tubular forms when expressed in isolation under defined conditions. (A) Different expression systems from prokaryotic E. coli [2, 72, 126] [49, 53, 92, 96, 102, 111] , drug delivery tools [5, 91, 122, 126] , and nano-biomaterials [5, 23, 24, 41, 42, 50, 91, 122, 126] 

Due to their superior immunogenicity compared to other VP6 preparations, VP6 tubes/VLPs have been selected for use in VP6-based RV vaccine candidates. Despite the challenges to efficient VLP generation on a large scale in insect cells, the establishment of IC-BV expression systems has been given high priority for production of VP6 tubes/VLPs. Indeed, in the first studies in 1987 [44] , a recombinant baculovirus encoding the VP6 gene of strain SA11 was used to express VP6 proteins capable of assembling into tubular structures while maintaining their native antigenic determinants and oligomeric structure [44] , and several studies demonstrated the immunogenicity of these insect-cell-derived VP6 tubes/VLPs. In this context, immunization of BALB/c mice with a combination of norovirus GII-4 VLPs and RV VP6 tubes resulted in a robust systemic cross-reactive and cross-blocking antibody response to both norovirus and RV [15], indicating sufficient immunogenicity of both Ags in the combined preparation without any dominance of one over the other.

In line with this finding, a trivalent combination vaccine containing norovirus GII-4 and GI-3 VLPs and RV VP6 tubes was also formulated by the same group of the researchers [108] . Immunization of mice with this trivalent vaccine demonstrated the ability of VP6 tubes to induce a robust, long-lasting, high-avidity IgG responses against various RV strains [108] . In still another study by the same group, the immunogenicity of the assembled VP6 tubes and double-layered (dl) 2/6-VLPs produced by coexpression of VP2 and VP6 was investigated [64] . The results indicated that this vaccine formulation induced a balanced Th1/Th2-type immune response with high levels of crossreactive serum IgG against different RV strains, as well as mucosal IgG and IgA Abs, and cellular immune responses with high levels of IFN-γ production [64] . Of particular note, the results of these and further studies indicated that mucosal VP6-specific Abs against VP6 tubes, which are found in the gut of immunized animals, might act as a first line of defense to inhibit infection by different RV strains in vitro and in vivo [64, 65, 108] . Similarly, other immunization studies in which VP6 assemblies were administered via the intramuscular or intranasal route in BALB/c mice indicated that serum VP6-specific IgA titers correlated with at least 65% protection against RV infection regardless of the delivery route [66] . These results suggested a significant role of mucosal immunity and VP6-specific IgA in inhibition of RV replication and heterotypic protection against RV infection. It should be noted, however, that immunization of BALB/c mice with VP6 tubes via the intradermal or intranasal route is also capable of generating diverse CD4 + T cell subsets and induction of the antiviral cytokine IFN-γ, interleukin-4 (IL-4), and the pro-inflammatory cytokine IL-17 [54] . The induction of such diverse cellular immune responses might imply that immunization with VP6 tubes provides protection against RV infection by other mechanisms besides intracellular inhibition by VP6-specific IgA and IgG.

In an attempt to assess the immunogenicity of the various assemblies of RV VP6 in vaccine formulations, the immune responses elicited by VP6 tubes, dl2/6-VLPs, and trimers were compared [95] , and the results indicated that immunization of mice with one dose of VP6 tubes induced the highest IgG titers and provided a level of protection against RV infection similar to that of two doses of either dl2/6-VLPs or trimers, suggesting the superiority of RV VP6 tubes for vaccine formulations [95] .

In addition to the baculovirus expression system, E. coli has also been used to produce various RV VP6 assemblies [18, [70] [71] [72] . The morphology of the E. coli-derived VP6 tubes/VLPs and trimers was verified using transmission electron microscopy (TEM) and atomic force microscopy (AFM) [18, 61, [70] [71] [72] 118] . Interestingly, the efficacy of the E. coli-derived VP6-VLPs or trimers against RV infection was significantly lower than that of E. coli-derived DLP2/6 [70] . In addition to baculovirus and E. coli expression systems, mammalian cells [38] and HSV-1-based vectors [90] as well as plant cells [37, 89, 127] have also been shown to have the capacity to produce self-assembled RV VP6 structures to induce protective immune responses against virus infection [78, 90] .

Overall, among the different RV VP6 preparations, VP6 tubes/VLPs might have the highest potential as a non-living RV vaccine platform due to their strong immunogenicity and maintenance of conserved epitopes.

Several studies have demonstrated the ability of RV VP6 tubes/VLPs to enhance immune responses against coadministered homologous/heterologous antigens (Fig. 1B) . The priming effect of immunization with the RV VP6 protein to enhance the generation of neutralizing Abs against heterotypic RV VP4 or VP7 proteins has been reported [43] . Several years later, in the early 2010s, the adjuvant effect of VP6 tubes/VLPs on a co-administered heterologous antigen (norovirus GI-3 protein), enhancing the induction of GI-3-specific cross-reactive Abs in the immunized mice, was shown [15] . In still another recent study, the adjuvant effect of VP6 tubes in mice immunized with suboptimal doses of norovirus GII.4 or GI.3 VLPs, either alone or in combination with VP6 tubes, was investigated [16] . The results of that study indicated that suboptimal doses of the norovirus VLPs alone did not induce substantial anti-norovirus Abs, but the combined vaccine induced considerable titers of cross-reactive Abs against both norovirus genotypes, indicating the adjuvant effect of RV VP6 on norovirus GII.4 or GI.3 VLPs [16]. It was later shown that the adjuvant effect of VP6 tubes on co-administered norovirus VLPs (as a mixture), compared to the separate administration of two antigens, is strictly dependent on co-localization of the VP6 with norovirus VLPs [77] . This finding was further supported by showing enhanced uptake of norovirus VLPs into antigen-presenting cells (APCs) [103] when mixed with VP6 tubes [76] . This process might induce the production of several cytokines/ chemokines (tumor necrosis factor [TNF]-α, IL-6, IL-1, and granulocyte macrophage colony-stimulating factor [GMCSF]), indicating the potential adjuvant effect of VP6 on norovirus-specific T-cell immunity [76, 77] . The potential roles of the administered dose and morphological features of the VP6 structural assemblies on their adjuvant activity were also addressed in studies on immunization with norovirus VLP [77] . In this context, it was shown that despite higher induction of the cytokine IL-4 by coadministration of VP6 tubes with norovirus VLPs than with VP6 VLPs, both of these oligomeric VP6 assemblies exerted a similar dose-dependent adjuvant effect on norovirus-specific Ab responses [77] . More-recent studies have indicated that the particulate nature and size of the co-administered Ag might also affect the adjuvant effect of VP6 VLPs [55] . In this context, co-administration of VP6 VLPs with either a 20-nm norovirus P particle or a 23-mer extracellular domain of matrix protein M2 (M2e, a monomeric peptide, ~3 kDa) of human influenza A virus showed an adjuvant effect of VP6 VLPs only, enhancing Ab and T-cell immune responses against the preceding Ag (norovirus P particle), and not M2e [55] . VP6 tubes/ VLPs have also been shown to enhance the uptake and presentation of co-administered norovirus GII.4 VLPs by dendritic cells [109, 110] . VP6 tube/VLP structures, and even their aggregates lacking high structural order, were efficiently internalized by bone-marrow-derived dendritic cells (BMDCs). Interestingly, compared to VP6 tube/ VLP structures, an increased level of internalization was observed by the aggregates. Although the reasons behind these observations still remain to be explained, similar levels of IFN-γ production by splenocytes of VP6-immunized mice were detected regardless of the structural assembly [109] . Finally, it is worth mentioning that similar adjuvant effects were observed when plant-derived VP6 tubes were co-administered with plant-derived norovirus VLPs, indicating the independence of this adjuvant characteristic on the source of the cell/host used for vaccine production [78] .

Overall, VP6 tubes/VLPs not only induce higher levels of immunogenicity compared to trimers or aggregates of VP6 but also have great potential to act as an adjuvant and to enhance prominent Ab and T-cell immune responses against foreign antigens.

The strong immunogenicity and inherent immunostimulatory and immunomodulatory characteristics of VP6 tubes/ VLPs make this structured protein assembly an important candidate vaccine-delivery platform for foreign/heterologous Ag presentation. The first reports on applications of RV VP6 spherical VLPs as antigen carriers were in the early 1990s, when heterologous peptides/proteins were efficiently coupled to these carriers and succssesfully used as strong immunogens to induce high titers of specific Abs against the coupled peptides/proteins without the use of adjuvants (Fig. 1B) [49, 102] . Since then, there have been many reports on the successful application of RV VP6 structured protein assemblies for chimeric Ag delivery, including insertion of (i) a 14-amino-acid peptide derived from the simian paramyxovirus 5 (V5 epitope) by genetic fusion [96] , (ii) three epitopes of poliovirus type 1 (PV1) [92] , (iii) three epitopes derived from the VP4 of RV [114] , (iv) two peptides (23 and 140 amino acids) derived from the M2 and hemagglutinin (HA) genes of influenza A virus [53] , and, more recently, (v) insertion of the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S) to the surface loops or the N-terminus of VP6 without affecting protein conformation and immunogenicity [111] . The results of the immunization studies using these VP6-based chimeric Ag delivery systems in animal models have demonstrated the potency of VP6-based structured protein assemblies (VP6 tubes/VLPs) for induction of high titers of Abs and strong T-cell immune responses against both VP6 and the inserted Ag, suggesting the conformational conservation of both Ags in the chimera.

Besides serving as immunological carriers, RV VP6 structured protein assemblies in the form of nanotubes/VLPs are capable of encapsulating therapeutic reagents for the purpose of drug delivery (Fig. 1B) [122, 126] . Indeed, owing to their biocompatibility, biodegradability, and encapsulation characteristics, such viral nanoparticles are suggested to act as carriers of targeted therapeutics and anticancer vehicles [122] . In this context, it has been reported that self-assembled RV VP6 particles fused to the small ubiquitin modifier (SUMO) domain maintain their nanotube/VLP structure in the gastrointestinal (GI) tract when administered orally and represent a suitable biodegradable carrier [5, 91, 122, 126] . These results suggest the potential application of self-assembled RV VP6 particles for drug delivery to the GI tract.

Biological molecules with the ability to self-assemble are highly ordered, symmetrical, homogeneous structures with various sizes and shapes [41] . Among the different biomolecules (nucleic acids, proteins, peptides, and viral particles), viral protein assemblies, which are highly ordered complex structures with multifunctional binding properties and devoid of genetic material, would be ideal as a new platform for the synthesis of natural nano-materials [41, 42] . One protein with these features is RV VP6, which is ideal for obtaining tubes/VLPs that can form multifunctional scaffolds for construction of organized nano-biomaterials (Fig. 1B) [23, 97, 99] . It has also been shown that RV VP6 in the context of trimer and nanotube assembly can act as a scaffold to allow charge transfer processes and to create bio-electrochemical interfaces [50] .

The selection of VP6 assemblies as scaffolds for the synthesis of the metallic nanoparticles, functionalized in situ with metals such as silver (Ag), gold (Au), platinum (Pt), and palladium (Pd) was first reported in 2009 [99] . Although functionalization with metals usually results to the formation of nanotubes/particles with the metal attached to the external surface [97] [98] [99] , reduction of the metal in situ to produce nanorods and nanowires inside the nanotubes has also been reported [23] . Finally, it is worth mentioning that molecular docking simulations have shown that exposed residues of RV VP6 are predicted to be able to bind to Pd (II) ions and to produce nucleation sites for the growth, stabilization, and control of Pd particles [24] .

Overall, the accumulated data indicate that RV VP6 tubes/VLPs can be used as scaffolds to generate nanotubes with metal on either the external or internal surface. These properties might find important applications in nano-biotechnology.

The highly conserved and abundant structural protein VP6 of RV is an immunogen that is capable of self-assembling into nano-sized spherical and tubular forms when expressed in isolation under defined conditions. Different expression systems from prokaryotic E. coli to eukaryotic systems such as yeast, insect cell/baculovirus systems, mammalian cells, and plant cells have been used successfully to produce assembled VP6 structures such as VP6 tubes/VLPs. These structures have been shown to be stronger immunogens than VP6 monomers for protecting vaccinated animals from RV infection and thus might be appropriate alternatives for RV vaccine formulations. VP6 tubes/VLPs also show adjuvant activity when co-administered with other Ags such as norovirus VLPs. This adjuvant activity, which involves enhanced uptake of the Ag into APCs, has been shown to be strictly dependent on co-localization of VP6 with norovirus VLPs. The applicability of VP6-tubes/VLPs as immunological carriers has been shown by fusing them to heterologous Ags from several viruses, such as polio virus, influenza virus, and SARS-CoV-2, and the successful delivery of the chimeric Ags. VP6 tubes/VLPs are biocompatible and biodegradable nanocompounds that are capable of encapsulating therapeutic reagents for treatment of diseases such as cancer. Finally, VP6 tubes/VLPs can form multifunctional scaffolds that can be used to create bio-electrochemical interfaces and for synthesis of organized nano-biomaterials and metallic nanoparticles. These properties of RV VP6 tubes/VLPs make them potentially suitable for various practical applications. 

Epizootic diarrhea of infant mice: identification of the etiologic agent

Immunization of mice by rotavirus NSP4-VP6 fusion protein elicited stronger responses compared to VP6 alone

Rotavirus VP6 as a potential vaccine candidate

Human rotavirus VP6-specific antibodies mediate intracellular neutralization by binding to a quaternary structure in the transcriptional pore

A protein chimera self-assembling unit for drug delivery

Candidate new rotavirus species in Schreiber's bats

Viral gastroenteritis

HEK293-T cells and insect cell-baculovirus system

Oral immunization with pBsVP6-transgenic alfalfa protects mice against rotavirus infection

Viruses: making friends with old foes

Organization of metallic nanoparticles using tobacco mosaic virus templates

The internal rotavirus protein VP6 primes for an enhanced neutralizing antibody response

Synthesis and immunogenicity of the rotavirus major capsid antigen using a baculovirus expression system

Rotavirus gene structure and function

Oral administration of a seed-based bivalent rotavirus vaccine containing VP6 and NSP4 induces specific immune responses in mice

Inhibition of rotavirus replication by a non-neutralizing, rotavirus VP6-specific IgA mAb

Letter: virus particles in gastroenteritis

Biochemical and immunological characterization of a novel peptide carrier system using rotavirus VP6 particles

Rotavirus VP6 protein as a bio-electrochemical scaffold: molecular dynamics and experimental electrochemistry

Biochemical evidence for the oligomeric (possibly trimeric) structure of the major inner capsid polypeptide (45K) of rotaviruses

Serological analysis of the subgroup protein of rotavirus, using monoclonal antibodies

Expression of influenza A virus-derived peptides on a rotavirus VP6-based delivery platform

Intradermal and intranasal immunizations with oligomeric middle layer rotavirus VP6 induce Th1, Th2 and Th17 T cell subsets and CD4+ T lymphocytes with cytotoxic potential

Rotavirus inner capsid VP6 acts as an adjuvant in formulations with particulate antigens only

DNA vaccines against rotavirus infections

Protection against rotavirus infections by DNA vaccination

Efficacy of a lowcost, heat-stable oral rotavirus vaccine in Niger

Rotavirus VP6 preparations as a non-replicating vaccine candidates

Biophysical properties of single rotavirus particles account for the functions of protein shells in a multilayered virus

Distantly related rotaviruses in common shrews

Reoviruslike agent in stools: association with infantile diarrhea and development of serologic tests

Comparative immunogenicity in mice of rotavirus VP6 tubular structures and virus-like particles

Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo

Protection against live rotavirus challenge in mice induced by parenteral and mucosal delivery of VP6 subunit rotavirus vaccine

Simple and efficient ultrafiltration method for purification of rotavirus VP6 oligomeric proteins

Structural polymorphism of the major capsid protein of rotavirus

Identification of novel and diverse rotaviruses in rodents and insectivores, and evidence of cross-species transmission into humans

Improved characteristics and protective efficacy in an animal model of E. coli-derived recombinant double-layered rotavirus virus-like particles

Self-assembling rotavirus VP6 nanoparticle vaccines expressed in Escherichia coli elicit systemic and mucosal responses in mice

A milk-based self-assemble rotavirus VP6-ferritin nanoparticle vaccine elicited protection against the viral infection

Determination of human rotavirus VP6 genogroups I and II by reverse transcription-PCR

Enhancement of VP6 immunogenicity and protective efficacy against rotavirus by VP2 in a genetic immunization

The cytopathic effects of vervet monkey viruses

Rotavirus recombinant VP6 nanotubes act as an immunomodulator and delivery vehicle for norovirus virus-like particles

Rotavirus capsid VP6 tubular and spherical nanostructures act as local adjuvants when co-delivered with norovirus VLPs

Rotavirus VP6 as an adjuvant for bivalent norovirus vaccine produced in Nicotiana benthamiana

Full genome-based classification of rotaviruses reveals a common origin between human Wa-Like and porcine rotavirus strains and human DS-1-like and bovine rotavirus strains

Recommendations for the classification of group A rotaviruses using all 11 genomic RNA segments

Uniformity of rotavirus strain nomenclature proposed by the Rotavirus Classification Working Group (RCWG)

VP6-sequence-based cutoff values as a criterion for rotavirus species demarcation

CD4 T cells are the only lymphocytes needed to protect mice against rotavirus shedding after intranasal immunization with a chimeric VP6 protein and the adjuvant LT(R192G)

Protection against rotavirus shedding after intranasal immunization of mice with a chimeric VP6 protein does not require intestinal IgA

Intrarectal immunization of mice with VP6 and either LT(R192G) or CTA1-DD as adjuvant protects against fecal rotavirus shedding after EDIM challenge

Intracellular distribution of rotavirus structural proteins and virus-like particles expressed in the insect cell-baculovirus system

Candidate new rotavirus species in sheltered dogs

Major findings and recent advances in virus-like particle (VLP)-based vaccines

Rotavirus VP6 expressed by PVX vectors in Nicotiana benthamiana coats PVX rods and also assembles into viruslike particles

Rotavirus VP6 protein expressed in cell culture by HSV-1-based vectors

VP6-SUMO self-assembly as nanocarriers for gastrointestinal delivery

Immunogenicity and antigenicity of a recombinant chimeric protein containing epitopes of poliovirus type 1

Global illness and deaths caused by rotavirus disease in children

Rotavirus and severe childhood diarrhea

The assembly conformation of rotavirus VP6 determines its protective efficacy against rotavirus challenge in mice

Chimeric recombinant rotavirus-like particles as a vehicle for the display of heterologous epitopes

Strategies for the purification and characterization of protein scaffolds for the production of hybrid nanobiomaterials

Structural characterization of rotavirusdirected synthesis and assembly of metallic nanoparticle arrays

Use of recombinant rotavirus VP6 nanotubes as a multifunctional template for the synthesis of nanobiomaterials functionalized with metals

Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design

In vitro assembly of bovine rotavirus nucleocapsid protein

Rotavirus particles function as immunological carriers for the delivery of peptides from infectious agents and endogenous proteins

Understanding internalization of rotavirus VP6 nanotubes by cells: towards a recombinant vaccine

A novel method for the in vitro assembly of virus-like particles and multimeric proteins

Hepatitis B core-based virus-like particles to present heterologous epitopes

Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis

Association of gamma interferon and interleukin-17 production in intestinal CD4+ T cells with protection against rotavirus shedding in mice intranasally immunized with VP6 and the adjuvant LT(R192G)

Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice

Internalization and antigen presentation by mouse dendritic cells of rotavirus VP6 preparations differing in nanostructure

Rotavirus VP6 adjuvant effect on norovirus GII. 4 virus-like particle uptake and presentation by bone marrow-derived dendritic cells in vitro and in vivo

Fusion protein of rotavirus VP6 and SARS-CoV-2 receptor binding domain induces T cell responses

estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis

World Health Organization-Coordinated Global Rotavirus Surveillance N (2016) Global, regional, and national estimates of rotavirus mortality in children <5 years of age

A new rotavirus VP6-based foreign epitope presenting vector and immunoreactivity of VP4 epitope chimeric proteins

Rotavirus vaccination and the global burden of rotavirus diarrhea among children younger than 5 years

IgY antibodies protect against human Rotavirus induced diarrhea in the neonatal gnotobiotic piglet disease model

Recombinant monovalent llama-derived antibody fragments (VHH) to rotavirus VP6 protect neonatal gnotobiotic piglets against human rotavirus-induced diarrhea

Automated image analysis of atomic force microscopy images of rotavirus particles

Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants

Safety Trial Study T (2006) Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine

VP6: a candidate rotavirus vaccine

Self-assembled viral nanoparticles as targeted anticancer vehicles

Immune responses and protection obtained with rotavirus VP6 DNA vaccines given by intramuscular injection

Expression of rotavirus capsid protein VP6 in transgenic potato and its oral immunogenicity in mice

Mucosal and systemic antibody responses and protection induced by a prime/ boost rotavirus-DNA vaccine in a gnotobiotic pig model

Self-assembled virus-like particles from rotavirus structural protein VP6 for targeted drug delivery

Oral administration of plant-based rotavirus VP6 induces antigen-specific IgAs, IgGs and passive protection in mice

Prime immunization with rotavirus VLP 2/6 followed by boosting with an adenovirus expressing VP6 induces protective immunization against rotavirus in mice